SAGE - Neurodegenerative Disorder-Focused Sage Therapeutics Stock Falls On Disappointing Parkinson's Data | Benzinga
Wednesday, Sage Therapeutics Inc (NASDAQ:SAGE) announced topline results from the PRECEDENT Phase 2 study of dalzanemdor (SAGE-718) in people with mild cognitive impairment in Parkinson’s Disease.
The PRECEDENT Study did not meet its primary endpoint of demonstrating a statistically significant difference from baseline in participants treated with once-daily dalzanemdor versus placebo on the Wechsler Adult Intelligence Scale Fourth Edition-IV (WAIS-IV) Coding Test score at Day 42.
WAIS-IV is the most advanced adult measure of cognitive ability.
Dalzanemdor (SAGE-718) was ...